'I'm a drug addict,' a columnist wrote. Then the backlash began.

David Lazarus, a business columnist for the Los Angeles Times, last week wrote a column detailing his struggles quitting antidepressants, but his article—titled "Hi, I'm David. I'm a drug addict"—received backlash from some critics for conflating addiction and physical dependence.

Read More
Advisory Board Insight Health Insurance 101

A new peanut allergy drug could cost $4,200 a year. Is it just overpriced peanut flour?

An FDA advisory panel this month recommended approval of an experimental treatment for peanut allergies, but writing in The Atlantic, James Hamblin questions whether the product is worth its likely $4,200 price tag—and flags research suggesting it may backfire for some patients.

8 ways you're making your employees quit (and how to do better)

Employee turnover is costly and can hurt productivity, but advances in data analytics are helping to identify specific leadership behaviors that cause workers to quit, Jon Christiansen, co-founder of Insights and Outcomes, writes for Harvard Business Review.

Our take: A federal judge just struck down Medicare's site-neutral payment rule

A federal judge on Tuesday vacated HHS' site-neutral payment policy that cuts Medicare payment rates for off-campus hospital facilities.

How Northwell created a 'culture of inquiry' among its nurses

In an interview with HealthLeaders Media's Jennifer Thew, two nursing leaders at Northwell Health explain how establishing a "culture of inquiry" improved care delivery, patient outcomes, and nurse engagement at the system.

How an alleged Groupon scam led these patients to get 'fake Botox'

Federal and state officials last week raided a plastic surgery office following accusations that a doctor at the clinic administered non-FDA-approved drugs to patients who purchased certain services through Groupon, adding to growing concerns that Groupon users might be more vulnerable to medical scams.

Around the nation: Federal judge blocks sale of Hahnemann University Hospital residency programs

A U.S. District Court judge on Monday blocked the bankruptcy sale of Hahnemann University Hospital's residency programs following an appeal by CMS, in today's bite-sized hospital and health industry news from Massachusetts, Pennsylvania, and Virginia.